Alembic Pharmaceuticals Gains USFDA Nod for Generic Anti-Worm Drug

Alembic Pharmaceuticals has received approval from the USFDA for its generic version of Albendazole Tablets USP (200 mg), used to treat worm infections. The drug is therapeutically equivalent to Impax Laboratories' Albenza tablets. Alembic's shares rose 2.79% following the announcement.

Alembic Pharmaceuticals announced on Thursday that it has received approval from the US health regulator to market a generic drug aimed at treating infections caused by worms.

The US Food & Drug Administration (USFDA) approved Alembic's Abbreviated New Drug Application (ANDA) for Albendazole Tablets USP (200 mg), the pharmaceutical company stated.

According to the company, the approved ANDA is therapeutically equivalent to Impax Laboratories, Inc.'s Albenza tablets. Albendazole tablets are prescribed for parenchymal neurocysticercosis due to active lesions from the pork tapeworm, Taenia solium. The tablets also treat cystic hydatid disease of the liver, lung, and peritoneum caused by the larval form of the dog tapeworm, Echinococcus granulosus. Alembic Pharma shares closed 2.79% higher at Rs 1,145.80 each on the BSE.

(With inputs from agencies.)